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Introduction [4]. There are seven antigenically distinct serotypes of 
FMDV (A, O, C, South African Territories (SAT) types  Foot and mouth disease (FMD) is an economically 
1–3 and Asia-1) and each serotype has many subtype  devastating disease of livestock. Although vaccines, 
variants.  This  antigenic  variation  creates  a  major  available since the early 1900s, have been instrumental 
problem  for  the  control  of  FMD,  as  infection  or  in eradicating FMD from parts of the world, the disease 
vaccination  with  one  serotype  of  FMDV  does  not  still affects millions of animals around the globe and 
protect against other serotypes and may fail to protect  remains the main sanitary barrier to the commerce of 
fully against other subtypes within the same serotype 
animals and animal products [1] [5].
Although mortality is usually low, morbidity can  Foot  and  mouth  disease  harvest  contain  three    reach  100%  causing  severe  losses  in  production.  virus specific particles: (i) the infective 146S virus  Therefore,  the  disease  remains  a  major  economic  particle, comprising one molecule of ss RNA and 60  concern for livestock-health in many developing countries  copies of each of four polypeptides VP1,VP2,VP3 and 
and a continued threat to disease free countries [2, 3] VP4; ( ii) the  empty 75S particles, devoid of RNA and 
The causative agent of FMD is a small positive  comprising 60 copies of each of VP1,VP3 and VP0 
sense ssRNA virus (approx. 8.3 kb) which belongs to  (precursor  of VP2  and VP4);  (iii)  the  12S  particle 
the Aphthovirus genus of the family Picornaviridae  consisting of VP1,VP2 and VP3 but devoid of VP4 [6]
In Egypt, the disease is enzootic and outbreaks 
have been reported since 1950. FMD serotypes 'SAT2', 
'A' and 'O' were reported in the years 2012, 1972 and 
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Abstract
Aim: To determine the minimal effective dose of Foot and Mouth disease (FMD) serotypes (A, O, SAT2) according to 
antigenic content (146S) in order to produce a potent trivalent FMD vaccine. 
Materials and Methods: Monovalent ISA 206 vaccines were prepared with 3 final concentration of 146S (1.6, 2.2, 2.8 
µg/dose). The vaccine potency was evaluated by the determination of guinea pig protective dose 50 (GPPD )for each  50
concentration of 146S for each type of FMD monovalent vaccine  where a fourfold dilution of the vaccines  was constructed 
and  each dilution was inoculated as 0.5 ml S/C in each of 5 guinea pigs.
Results: The obtained results revealed that by using 1.6 µg of 146S for type O Pan Asia-2, A Iran O5 and SAT/EGY/2012, the 
GPPD  was 40.4, 19.75 and 31.6 respectively, while the use of 2.2 µg of 146S resulted in GPPD  78.6, 78.6 and 105.8 for the  50 50
three types respectively, and by using 2.8 µg of 146S resulted in GPPD  161.7, 105.8 and 161.7 for the three subtypes (A, O,  50
SAT2) respectively. So it is clear that the lowest 146S dilution inducing good protection (more than 72 GPPD ) was 2.2 µg for  50
each serotype of used FMD monovalent vaccines. Depending on this result, the trivalent vaccine was formulated as 2.2 µg of 
146S payload from each virus type/dose with equal volume of montanide ISA 206 oil as adjuvant. For more confirmation the 
prepared trivalent vaccine potency was evaluated by Guinea pig protective dose 50 which was found to be 88 GPPD .Also  50
mean SNT antibody titer was detected in serum of the test Guinea pigs 1.56, 1.68 and 1.68 log /ml against FMDV serotype O  10
Pan Asia-2, A Iran O5 and SAT/EGY/2012 respectively in a higher level than the recommended protective titer (PT=1.2). Also 
for further confirmation the formulated trivalent vaccine which contain 2.2 µg/serotype/dose were evaluated in cattle to 
measure the antibody titer against the three serotypes and the antibody against the three serotypes were found to be higher than 
the recommended titer (1.5) which extended for 32 WPV and these results came in parallel manner to the GPPD  and antibody  50
titer of the Guinea pigs of the prepared trivalent vaccine with 146S (2.2 µg/serotype/dose).
Conclusion: It could be concluded that the minimum content of antigenic 146S of FMDV serotype O pan Asia, A Iran O5 and 
SAT2/EGY/2012 should not be less than 2.2 µg/dose/ from each serotype in the trivalent vaccine aiming to induce the 
permissible protection in vaccinated livestock.
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2000,  respectively  [7-10].  Virus  type  'O'  was  which  is  evaluated  as  GPPD ,  determination  of  50
incriminated in the last two epidemic outbreaks, which  antibodies in G. Pigs and cattle, so as to be safe and 
occurred in 1987 and 1993.  potent. In addition, determination of the optimal 146S 
Vaccination is the only approach to control FMD.  content  aids  to  avoid  the  challenge  of  vaccinated 
The immunogenicity of foot and mouth disease (FMD)  animals during the vaccine evaluation test which may 
vaccines depends to a large extent on the production of  result in infection of animals with the virulent viral 
whole virions (146S particles), in tissue culture and the  strains. 
stability  of  these  particles  after  virus  inactivation 
Materials and Methods procedures and formulation into vaccines. [11].
Experimental guinea pigs: Healthy adult male albino  The  quantity  of  146S  particles  in  inactivated 
guinea pigs approximately of 400-500 gm body weight  FMD virus vaccine samples produced in FMD Vaccine 
were used for preparation of guinea pig adapted FMD  Production  Center  is  generally  estimated  by  the 
virus  to  be  used  for  Guinea  pig  challenge  and  for  sucrose  gradient  ultracentrifugation  and  optical 
determination of GPPD  of the prepared vaccines. density  analysis  by  using  the  computer  applying  50
system [12].
Ethical  approval:  The  experiment  was  as  per  the  The use of 146S assay only or some serological  protocol of Institutional Animal Ethics Committee, the  tests which together increase the reliance on estimating  authors  had  taken  permission  of  animal  owners  of  potency of specific vaccine batch. They can also be  private farm.  assembled with an interconnected method which is 
based on the 146S concentration of the final vaccine 
Tissue  culture:  Baby  hamster  kidney  cell  cultures  batch [13]. (BHK ) were obtained from the World Reference Lab.  21 It is well known that vaccination is the basic step 
Pirbright Surrey, U.K. The cells were serially passaged  and corner stone in controlling FMD as other viral 
and  maintained  with  Minimum  Essential  Medium  infectious diseases. The used vaccine in Egypt was the 
(MEM) modified with Hank's salt with 1-2 % bovine  cell culture inactivated bivalent vaccine prepared from 
serum in the FMD Research Department, Veterinary  the local strain O /3/1993 and type A/1/EGY/ 2006).  1 Serum and Vaccine Research Institute, Abbasia, Cairo  Nowadays and after isolation of the recent FMD O pan  [18].  Asia, A Iran O5 [14] and SAT2/2012 [10] a new locally 
FMD Virus strains trivalent inactivated vaccine was generated containing 
Tissue  culture  FMD  virus:  Local  Foot  and  Mouth  the three types of the virus.
disease virus types O panAsia, A Iran O5 and SAT2/  Vaccine manufacturers evaluate the efficiency of 
EGY/2012were  propagated  in  BHK   cell  line  21 their vaccine according to the method which is defined 
monolayer cultures for preparation of virus infected  in the European Pharmacopoeia. Regarding foot-and-
fluids in the Department of Foot and Mouth Diseases  mouth  disease  (FMD)  vaccine  there  are  some 
Research,  Veterinary  Serum  and  Vaccine  Research  difficulties to find animals for potency tests in the 
Institute. The titer of the three types was expressed in  countries  like  Turkey  where  FMD  is  endemic  and 
log TCID  as described earlier [19] and the CF was  vaccine campaigns are carried out. In addition, potency  10 50
carried out according to earlier reports [20, 21].  tests must be carried out in containments having high 
biosecurity  levels.  There  are  many  publications 
Guinea pig adapted virus: Albino Guinea pigs were 
indicating a correlation between protections from virus  inoculated by FMD virus strain O pan Asia-2, A Iran 
challenge  and  neutralizing  antibody  response.  O5 and SAT2 / EGY/2012 intradermoplanter in the 
However, up to now, none of the suggested method has  metatarsal  pads.  After  24-48  hours  the  developed 
been found valid [13]. lesions were collected aseptically. The lesions extract 
Guinea pigs were chosen as experimental models  was again re-inoculated in other Guinea pigs 5 times 
to  develop  concepts  and  techniques  to  study  the  until the virus became quite adapted to Guinea pigs as 
protective dose 50 (PD ) of FMD vaccines because of  50 recommended earlier [22].
the similarities of clinical symptoms in these animals to 
Virus purification: Aseptically, the harvested culture  those of swine and cattle to saving cost [15, 16]. Guinea 
medium from FMD virus infected BHK  cell cultures  pigs  are  susceptible  animals  to  FMD  and  can  be  21
protected by aqueous FMD vaccines. The methods of  were centrifuged in a cooling centrifuge at 7000 rpm 
demonstrating  the  potency  of  such  vaccines  using  for 20 minutes to remove cell debris [23].
Guinea  pigs  have  been  described  having  a  good  Virus inactivation
correlation with the protection afforded to cattle [17].
th Each  FMD  virus  (O, A  and  SAT2)  of  the  7   So the present work was designed to determine 
passage on BHK monolayer with an infectivity titer of  the minimal ideal dose of each of three monovalent 
8 10  TCID /dose  was  treated  with  1.5%  chloroform  50 FMD  vaccines  depending  on  its  antigenic  content 
then the inactivation occur by using combination of  (146S)  and  detection  of  vaccine  potency  which  is 
BEI 1mM and 0.04% FA (BEI-FA) according to the  expressed  as  50%  Guinea  pig  protective  doses 
method described previously [24, 25]. 2% of each of  (GPPD ) aiming to produce a potent trivalent vaccine  50Available at www.veterinaryworld.org/Vol.6/Nov-2013/3.pdf
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sodium  thiosulphate  (20%)  and  sodium  bisulphite  4-5 days of the challenge test for the development of 
(20%)  were  added  after  inactivation  process  to  primary and secondary lesions. If the virus generalizes 
neutralize the excess of BEI and formalin. in  the  guinea  pig's  body,  the  vesicles  on  the  un-
inoculated  feet  and  the  tongue  are  observed  for  a  Concentration of the FMD virus serotypes
positive reaction to the FMDV infection in guinea pigs. 
The  tissue  culture  viral  fluids  of  the  three  The observations were recorded and the Protection 
serotypes (O pan Asia-2, A Iran O5 and SAT2/ EGY/  Dose50 (PD ) was calculated in all groups and the  50 2012) were centrifuged at 7000 revolution/ minute for  control groups.
30 minutes and then concentrated by PEG-6000 to 
Preparation of trivalent FMD vaccine reach to 1/10 of its original volume.
The trivalent FMD vaccine (containing serotypes  Estimation  of  antigenic  content  (Total  protein  and 
146S) in FMD virus types O pan Asia-2, A Iran O5 and SAT2/Egy/2012) with 
Montanide ISA 206 was formulated from the lowest  Protein estimation of FMD prepared antigen was 
concentration  of  146S  from  each  serotype  yielding  performed by Bradford's method .The concentration of 
high protective GPPD  through the first part of the  50 146S particles in the virus preparation was estimated 
present work. This vaccine was inoculated as 0.5ml in  by using sucrose density gradient ultracentrifugation 
each of 5groups of Guinea pigs and each group was  by determining the absorbance at 254 nm using ISCO 
challenged with one of the FMD viral serotype (either  520 C Density Gradient system as described previously 
O pan Asia-2 or A Iran O5 or SAT2/EGY/2012) after 4  [26, 27].
weeks. Serum samples were collected pre-vaccination 
Formulation of FMD vaccine with Montanide ISA 206
and  weekly  for  4  weeks  post  vaccination.  Serum 
Vaccine formulation was done according to the  neutralization  test  was  performed  on  the  serum 
method described earlier [28, 29] as follows: The oil  samples as described earlier [31] and the antibody titer 
phase consisted of Montanide ISA 206, mixed as equal  was expressed as log . 10 parts of an aqueous and oil phase weight/weight, and 
Field  application  to  the  prepared  trivalent  FMD  oil  mixed thoroughly. 
vaccine in cattle farm Each of FMD monovalent vaccines was prepared 
In Fayoum governorate, cattle farm was vaccinated  with three concentrations of 146S finally adjusted to be 
with the experimental trivalent FMD oil vaccine batch  1.6µg, 2.2 µg, and 2.8µg viral particles/dose/serotype.
to determine the efficacy and the duration of immune  Trivalent FMD oil vaccine was formulated from 
response  which  induced  with  the  prepared  vaccine  minimum concentration of 146S from each serotype 
according to its 146S concentration. Serum neutralization  which gave a high GPPD . 50
test was performed on the serum samples as described 
Potency test of prepared vaccines earlier [31] and the antibody titer was expressed as 
log . It was carried out through determination of the  10
Guinea pigs protection dose 50 (GPPD ) according to  50 Results and Discussion
earlier reports [17, 30] where Guinea pigs were divided 
FMD is still represent a non neglectable problem  into 10 groups as following:
st in  livestock  in  many  countries  resulted  in  huge  * Each of the 1 three groups was vaccinated with 
economic  loses  especially  developing  countries.  FMD (O pan Asia-2) with either concentration of 
Regarding Egypt several outbreaks attack the country  146S, using four fold dilution from such vaccine 
due to the infection with either type O, A, SAT2 [7].  (undiluted, 1/4, 1/16, 1/64, 1/256). Each dilution 
Through the last years monovalent FMD vaccine type  was inoculated as 0.5ml S/C in each of 5 Guinea 
O was used for several years where it was the only  pigs.
nd recorded type in Egypt [32], after that and according to  * Each of the 2  three groups was vaccinated with 
the  introduction  of  type  A,  bivalent  vaccine  was  FMD (A Iran O5) in the same manner as FMD (O 
successfully prepared containing both type O and A [8,  pan Asia-2).
rd 28, 29, 30,33]. More recently FMDV type SAT2 was  * Each of the 3  three groups was vaccinated with 
recorded  in  Egypt  [10,  34]  and  this  required  the  FMD (SAT2/EGY/2012) in the same manner as 
preparation of a trivalent vaccine containing the three  FMD (O pan Asia-2).
th present serotypes (A, O, SAT2). So, the present study  * The 4  group contained 5 Guinea pigs were kept 
was planned as a preliminary work to establish such  as non vaccinated control group.
vaccine through the determination of the minimal 146S  After 3 weeks, all Guinea pigs in all groups were 
content of each used serotype inducing the highest  challenged with its specific Guinea pig adapted FMD 
GPPD . virus;  by  inoculation  intra-dermoplanter.  The  50
challenged Guinea pigs were observed for 7 days till  The concentration of antigen per dose indirectly 
generalization of infection. determines  the  duration  of  immunity.  Further,  the 
The GPPD  was calculated according to previous  quantity of antibody induced and particularly, initial  50
magnitude  of  the  immune  response  determines  the  reports [16,19,22]. The Guinea pigs were checked after Available at www.veterinaryworld.org/Vol.6/Nov-2013/3.pdf
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duration of effective immunity. The  GPPD   was  estimated  to  determine  the  50
It is well established that the major immunogenic  protective  dose  for  Guinea  pigs  from  each  146S 
component of the FMDV is the intact 146S particle or  concentration(1.6  µg,  2.2  µg  and  2.8  µg)for  each 
antigen payload [35]. serotype of FMDV. It was found that using 1.6µg of 
The obtained result revealed that the virus titers of  146S, the GPPD  was 40.4, 19.75 and 31.6 for (O Pan  50
the FMDV serotypes (O Pan Asia-2, A Iran O5 and  Asia-2, A Iran O5 and SAT/EGY/2012) respectively, 
SAT/EGY/2012) were 8.5, 9and 8.8 log  TCID /ml  10 50 while using 2.2 µg, the GPPD  was 78.6, 78.6 and105  50
with CFT value of 64, 32 and 32; total protein of the  for  O  Pan Asia-2, A  Iran  O5  and  SAT/EGY/2012) 
FMDV 3.8, 3.7 and 3.5 mg/ml and 146S antigenic  respectively, but using 2.8µg of 146S, induced GPPD50 
content 4, 3.5 and 3 µg/ml before the concentration  was 161.7, 105.8 and 161.7 for O Pan Asia-2, A Iran O5 
respectively but the 146S was reached to 5.7, 5.2 and  and  SAT/EGY/2012  respectively.  These  results  are 
4.8 µg/ml after concentration with PEG as tabulated in  tabulated in Table-2, 3, 4, and 5. These results were in 
Table-1. As vaccine preparation procedure described  agreement with earlier report [37] which used same 
earlier [14, 36], where it was mentioned that infectivity  FMD vaccine virus where in 2.2 µg of the antigen was 
of FMD virus samples was determined by cell culture  required to obtain 1 PD50 although, protection was 
methods. All of the virus samples were inoculated on  observed even with lower antigen dose. On the other 
BHK   cells;  also,  their  titration  was  obtained  by  21 side, these results disagree with another report [38] 
TCID  methods. The antigenicity of the virus samples  50 who mentioned that many trials have been conducted 
were studied by the Complement Fixation Test (CFT). to correlate the quantity of 146S virus particles per 
Table-1. FMD virus titer, CF value, total protein and 146S concentration
FMD virus types Titer (log  TCID50/ml) CFT Value Total protein (mg/ml) 146S(µg/ml)  146S after concentration (µg/ml) 10
O Pan Asia-2
A Iran O5 9 32 3.7 3.5 5.2
SAT-2/Egy. 2012 8.8 32 3.5 3 4.8
8.5 64 3.8 4 5.7
Table-2. GPPD  of FMD virus type O panAsia-2 with different 146S content vaccine 50
Vaccine     VG PG NPG CPG CNPG Protection %
dilution
1.6* 2.2* 2.8* 1.6* 2.2* 2.8* 1.6* 2.2* 2.8* 1.6* 2.2* 2.8* 1.6* 2.2* 2.8* 1.6* 2.2* 2.8*
Un diluted 5 5 5 5 5 5 0 0 0 16 18 21 0 0 0 100 100 100
1/4 5 5 5 5 5 5 0 0 0 11 13 16 0 0 0 100 100 100
1/16 5 5 5 4 4 5 1 1 0 6 8 11 1 1 0 85.7 88.8 100
1/64 5 5 5 2 3 4 3 2 1 2 4 6 4 3 1 33.3 57.1 85.7
1/256 5 5 5 0 1 2 5 4 3 0 1 2 9 7 4 0 12.5 33.3
VG: No. of vaccinated guinea pigs, PG: No. of protected guinea pigs,  NPG: No. of non protected guinea pigs, CPG: Cumulative no. of protected 
guinea pigs, CNPG: Cumulative no. of non protected guinea pigs, (* 146S µg/ml), GPPD  (1.6µg 146S of O) = 40.6, GPPD  (2.2 µg 146S of O) =  50 50
78.6GPPD  (2.8 µg 146S of O) = 161.7 50
Table-3 GPPD  of FMD virus type A Iran O5 with different 146S content vaccine. 50
Vaccine     VG PG NPG CPG CNPG Protection %
dilution
1.6* 2.2* 2.8* 1.6* 2.2* 2.8* 1.6* 2.2* 2.8* 1.6* 2.2* 2.8* 1.6* 2.2* 2.8* 1.6* 2.2* 2.8*
Un diluted 5 5 5 5 5 5 0 0 0 13 18 19 0 0 0 100 100 100
1/4 5 5 5 4 5 5 1 0 0 8 13 14 1 0 0 88.8 100 100
1/16 5 5 5 3 4 4 2 1 1 4 8 9 3 1 1 57.1 88.8 90
1/64 5 5 5 1 3 4 4 2 1 1 4 5 7 3 2 12.5 57.1 71.4
1/256 5 5 5 0 1 1 5 4 4 0 1 1 12 7 6 0 12.5 14.2
VG: No. of vaccinated guinea pigs, PG: No. of protected guinea pigs,  NPG: No. of non protected guinea pigs, CPG: Cumulative no. of protected 
guinea pigs, CNPG: Cumulative no. of non protected guinea pigs, (*146S µg/ml), GPPD  (1.6µg 146S of A) = 19.75, GPPD (2.2 µg 146S of A)  50 50 
= 78.6, GPPD (2.8 µg 146S of A) = 105.8 50 
Table-4. GPPD  of FMD virus type SAT2/EGY/2012 with different 146S content vaccine 50
Vaccine     VG PG NPG CPG CNPG Protection %
dilution
1.6* 2.2* 2.8* 1.6* 2.2* 2.8* 1.6* 2.2* 2.8* 1.6* 2.2* 2.8* 1.6* 2.2* 2.8* 1.6* 2.2* 2.8*
Un diluted 5 5 5 5 5 5 0 0 0 15 19 21 0 0 0 100 100 100
1/4 5 5 5 5 5 5 0 0 0 10 14 16 0 0 0 100 100 100
1/16 5 5 5 4 4 5 1 1 0 5 9 11 1 1 0 83.3 90 100
1/64 5 5 5 1 4 4 4 1 1 1 5 6 5 2 1 16.6 71.4 85.7
1/256 5 5 5 0 1 2 5 4 3 0 1 2 10 6 4 0 14.3 33.3
VG: No. of vaccinated guinea pigs, PG: No. of protected guinea pigs,  NPG: No. of non protected guinea pigs, CPG: Cumulative no. of protected 
guinea pigs, CNPG: Cumulative no. of non protected guinea pigs, (*146S µg/ml), GPPD  (1.6µg 146S of SAT2) = 31.6, GPPD (2.2 µg 146S of  50 50 
SAT2) = 105.8, GPPD  (2.8 µg 146S of SAT2) = 161.7 50Available at www.veterinaryworld.org/Vol.6/Nov-2013/3.pdf
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vaccine  dose  and  the  protection  and  immunity  respectively. Such titers appear to be higher than the 
achieved.  The  minimum  effective  dose  of  purified  recommended  protective  titer  (1.2).  These  results 
FMDV A-119 required for eliciting virus-neutralizing  indicate that the prepared trivalent FMD vaccine able 
immune response in guinea pigs was about 1.6 µg. This  to  induce  acceptable  immune  level  in  vaccinated 
disagreement  could  be  attributed  to  the  different  Guinea pigs where the obtained antibody titers against 
subtype of FMDV type A used in this experiment. the  three  types  were  found  to  be  higher  than  the 
Also  as  in  Table-5,  the  mean  neutralizing  recommended  titer  (PT=1.2)  coming  in  a  parallel 
antibody titer of the Guinea pigs vaccinated with FMD  manner to that of GPPD . These finding coming in  50
vaccine  with  1.6,  2.2,  2.8  µg  indicated  that  the  agreement with those of earlier report [36] who found 
neutralizing antibody was protected using 146S 2.2  that after the vaccines were inoculated subcutaneously 
and 2.8µg/ml with all serotype while the SNT was 0.9,  on the back foot in two groups of guinea pigs, just two 
0.7 and 0.7 using 1.6 µg/ml of 146S for (O Pan Asia-2,  of ten animals showed antiserum titration above the 
A Iran O5 and SAT/EGY/2012) respectively but it was  protective titer (PT=1.2), and the other 8 animals were 
1.6, 1.55, 1.7 using 2.2 µg/ml of 146S for (O Pan Asia- below the PT.
2, A Iran O5 and SAT/EGY/2012) respectively also it  Finally we used the Guinea pigs as model for 
was 1.84, 1.75, 1.86 using 2.8 µg/ml of 146S for (O Pan  vaccine evaluation instead of cattle to lower the cost 
Asia-2, A Iran O5 and SAT/EGY/2012) respectively.  during  the  vaccine  evaluation,  so  to  confirm  these 
These findings are in agreement with previous report  results we made field application to the experimental 
[36] that showed that the protective titer of SNT in  prepared vaccine to confirm that the amount of 146S 
Guinea pigs is 1.2. used  is  sufficient  to  protect  cattle  from  FMDV,  as 
The  above  mentioned  results  indicate  that  the  shown in Table-8, the serum neutralizing antibody titer 
lowest concentration of 146S which resulted in good  against the three serotypes (A,O,SAT) in cattle for 36 
protection;  through  determination  of  GPPD (more  week  post  vaccination  (WPV).  The  results  were  50 
than 72 as mentioned earlier [39]); was 2.2 µg for each  confirmatory to the previous results as the SN antibody 
serotype (O Pan Asia-2, A Iran O5 and SAT/ EGY/  titer against serotype (O) started as 0.3 at 0WPV and 
2012). reached its maximum antibody level at 10WPV (3.15) 
The new formulated prepared vaccine as 2.2 µg of  and extended as a protective SN antibody titer from 2 to 
146S payload from each virus type with equal volume  32 WPV while the antibody titer against serotype (A) 
from the oil was diluted (undiluted, ¼, 1/16, 1/64,  started  as 0.3 at 0 WPV and reached its maximum titer 
1/256) and each dilution was inoculated in each of 5  at 8,10 and 12 WPV, the protective (1.5) extended from 
Guinea pigs. The obtained GPPD was found to be 88  2 to 34WPV. The SN antibody titer against FMDV  50 
as shown in Table-6. Such obtained GPPD50 appeared  serotype (SAT) was zero at 0 WPV and reached its 
to be higher than the recommended one, the thing that  maximum  antibody  titer  (3.15)  at  10  WPV,  the 
confirms the high potency of the prepared vaccine. protective antibody titer (1.5) extended from 2 to 32 
Testing of Guinea pigs serum samples, to confirm  WPV. From these results, the antibody titer against the 
the results of GPPD  using SNT, showed antibody  three  serotypes  were  found  to  be  higher  than  the  50
recommended titer (1.5) which extended for 32 WPV  titers of 1.56, 1.68 and 1.68 log /ml against FMDV  10
and these results came in parallel manner to the GPPD   serotype O Pan Asia-2, A Iran O5 and SAT/EGY/2012  50
Table-5. GPPD  of different 146S concentrations of FMD virus serotypes and mean serum neutralizing antibody after 28 day  50
post vaccination in Guinea pigs
Types of FMD virus 146S conc.(µg/ml) GPPD50 Mean serum neutralizing antibody after 28 day post
vaccination in Guinea pigs
FMDV type O panAsia-2 1.6 40.6 0.9
2.2 78.6 1.6
2.8 161.7 1.84
FMDV type  A Iran O5 1.6 19.75 0.7
2.2 78.6 1.55
2.8 105.8 1.75
FMDV type SAT2 /Egy/2012 1.6 31.6 0.7
2.2 105.8 1.7
2.8 161.7 1.86
GPPD  consider protective if it is more than 72 [22], The protective SN antibody is 1.2 [36] 50
Table-6. GPPD  of trivalent FMD vaccine (type O panAsia-2, A IranO5 and SAT2/EGY/2012) 50
Vaccine dilution No. of Guinea pigs No. of survived No. of affected CS CA Protection %
Undiluted 5 5 0 18 0 100%
1/4 5 5 0 13 0 100%
1/16 5 4 1 8 1 88%
1/64 5 4 1 4 2 66%
1/256 5 0 5 0 7 0%
GPPD  = 88 50Available at www.veterinaryworld.org/Vol.6/Nov-2013/3.pdf
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and antibody titer of the Guinea pigs of the prepared  (1.5 log  for SNT and 1.9 log  for ELISA) for both of  10 10
th trivalent  vaccine  with  146S  (2.2  µg/serotype/dose)  type A and O as estimated by SNT and ELISA on the 4  
these results come in agreement with previous reports  week post vaccination to record peak titers by the 12 
[28, 30, 33, 40] who mentioned that vaccination of  week post vaccination for both types. These antibody 
calves with the locally produced bivalent FMD vaccine  titers remained within the protective level up to 36 
adjuvanted with Montanide ISA 206 induced higher  weeks post vaccination in the 2 farms under study.
antibody titers than the recommended protective level 
Table-7. FMD serum neutralizing antibody titters in Guinea pigs vaccinated with trivalent FMD inactivated ISA 206 oil 
vaccine 
Animals  FMD serum neutralizing antibody titer (log10/mL)  Challenge
group 0 WPV* 1 WPV 2WPV 3WPV 4WPV
A O SAT2 A O SAT2 A O SAT2 A O SAT2 A O SAT2
1 0.3 - - 0.75 - - 1.2 - - 1.5 - - 1.65 - - A
2 0.15 - - 0.6 - - 0.9 - - 1.35 - - 1.5 - - A
3 0.3 - - 0.9 - - 1.05 - - 1.35 - - 1.5 - - A
4 0.3 - - 0.9 - - 1.35 - - 1.5 - - 1.65 - - A
5 0.15 - - 0.6 - - 1.05 - - 1.35 - - 1.5 - - A
Mean 0.24 - - 0.75 - - 1.11 - - 1.41 - - 1.56 - -
6 - 0.45 - - 0.9 - - 1.35 - - 1.65 - - 1.8 - O
7 - 0.3 - - 0.6 - - 1.05 - - 1.5 - - 1.65 - O
8 - 0.3 - - 0.6 - - 1.05 - - 1.35 - - 1.65 - O
9 - 0.45 - - 0.9 - - 1.35 - - 1.35 - - 1.5 - O
10 - 0.3 - - 0.75 - - 1.2 - - 1.5 - - 1.8 - O
Mean - 0.36 - - 0.75 - - 1.2 - - 1.47 - - 1.68 - -
11 - - 0.15 - - 0.6 - - 1.05 - - 1.35 - - 1.65 SAT-2
12 - - 0.3 - - 0.75 - - 1.2 - - 1.35 - - 1.5 SAT-2
13 - - 0.3 - - 0.75 - - 1.2 - - 1.5 - - 1.65 SAT2
14 - - 0.3 - - 0.9 - - 1.35 - - 1.65 - - 1.8 SAT-2
15 - - 0.45 - - 0.9 - - 1.35 - - 1.65 - - 1.8 SAT-2
Mean - - 0.3 - - 0.78 - - 1.23 - - 1.5 - - 1.68 -
16 0.45 - - 0.45 - - 0.45 - - 0.3 - - 0.3 - - A
17 0.3 - - 0.3 - - 0.3 - - 0.3 - - 0.3 - - A
18 0.3 - - 0.3 - - 0.3 - - 0.3 - - 0.3 - - A
19 - 0.3 - - 0.3 - - 0.3 - - 0.3 - - 0.3 - O
20 - 0.3 - - 0.3 - - 0.3 - - 0.3 - - 0.3 - O
21 - 0.3 - - 0.3 - - 0.3 - - 0.3 - - 0.3 - O
22 - - 0.15 - - 0.15 - - 0.15 - - 0.15 - - 0.15 SAT-2
23 - - 0.3 - - 0.3 - - 0.3 - - 0.3 - - 0.3 SAT-2
24 - - 0.3 - - 0.3 - - 0.3 - - 0.3 - - 0.3 SAT2
25 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 -
26 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 -
27 0.45 0.15 0.3 0.45 0.15 0.3 0.45 0.15 0.3 0.45 0.15 0.3 0.45 0.15 0.3 -
* WPV: Weeks post vaccination; 1-5 vaccinated with trivalent FMD oil vaccine and challenged with FMDV type A after 4WPV; 6-10 vaccinated 
with trivalent FMD oil vaccine and challenged with FMDV type O after 4WPV; 11-15 vaccinated with trivalent FMD oil vaccine and challenged with 
FMDV type SAT2 after 4WPV; 16-18 control positive inoculated with FMDV type A; 19-21 control positive inoculated with FMDV type O 
22-24 control positive inoculated with FMDV type SAT2; 25-27 control negative non vaccinated non infected Guinea Pigs
Table-8. Mean FMD serum neutralizing antibody titters in cattle vaccinated with trivalent FMD inactivated ISA 206 oil vaccine
Weeks post vaccination Mean FMD serum neutralizing antibody titer in cattle farm
O A SAT-2
0 0.3 0.3 0.0
1 1.2 1.2 1.05
2 1.8 1.8 1.5
3 2.1 2.1 1.8
4 2.4 2.55 2.1
6 2.8 2.8 2.4
8 3 3.15 2.85
10 3.15 3.15 3.15
12 3.0 3.15 3.0
14 2.7 2.85 2.85
16 2.55 2.7 2.7
18 2.55 2.4 2.55
20 2.25 2.4 2.25
22 2.1 2.25 2.1
24 2.1 2.1 1.8
26 1.95 1.8 1.8
28 1.8 1.8 1.8
30 1.65 1.65 1.65
32 1.5 1.65 1.5
34 1.35 1.5 1.35
36 1.2 1.35 1.2
Antibody titer expressed in log ; Protective SN antibody titer is 1.5 [14] 10Available at www.veterinaryworld.org/Vol.6/Nov-2013/3.pdf
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